Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
In the news
Recent Posts
Positive New Data and Strong Recruitment in Pancreatic Cancer Trial
Amplia Enters into Preclinical Collaboration with Korean Specialist Drug Screening Company Next&Bio
Interim Data from ACCENT Pancreatic Cancer Trial
Dr Chris Burns elected as a Fellow to the Australian Academy of Health and Medical Sciences (AAHMS)
ASX Briefs podcast | Interview with Dr Chris Burns
Recruitment Restarts in Accent Pancreatic Cancer Trial
Categories
Archive
Company News
Investor Newsletters
Videos
27 Sep 2024
Bulls ‘n Bears interview with Dr Chris Burns
Read More
23 Sep 2024
Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial
Read More
20 Sep 2024
FDA Fast Track Designation Granted to Narmafotinib in Pancreatic Cancer
Read More
12 Sep 2024
Investor Newsletter | September 2024
Read More
1
